Tuberculosis causes enormous social and economic damage due to the fact that, in general, it affects the working age population, requires long-term care, medical examination and hospitalization, and it needs prevention and anti-relapse measures.
To date the Company develops 2 antituberculosis drugs: SQ109 and Q203.
SQ109 based on the development of the U.S. biotechnology company Sequella, is one of some antituberculosis drugs that are at the late phase of clinical development. Load more…
The second drug Q203 licensed from Korean biotechnology company Qurient Co Ltd, is the first in new class of amide imidazopyridine compounds. Q203 has a unique mechanism of action against M. tuberculosis. Load more…